ProCE Banner Activity

TROPION-Breast01: Phase III Trial of Datopotamab Deruxtecan vs Chemotherapy for Patients With Previously Treated HR+ HER2- Metastatic Breast Cancer


In the primary analysis of the phase III TROPION-Breast01 trial for patients with previously treated, HR+/HER2- metastatic breast cancer, datopotamab deruxtecan showed a PFS benefit vs investigator’s choice of chemotherapy, meeting a coprimary endpoint.

Released: October 31, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.


Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.


Regeneron Pharmaceuticals, Inc